Lv41
596 积分 2023-07-05 加入
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
4小时前
已完结
Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma
9天前
已完结
Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma
22天前
已完结
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
24天前
已完结
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
26天前
已完结
Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma
27天前
已完结
Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma
27天前
已完结
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
27天前
已完结
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
28天前
已完结
The benefit and risk of adding PD-1/PD-L1 inhibitors plus anti-VEGF drugs to transarterial chemoembolisation for unresectable, non-metastatic hepatocellular carcinoma: a pooled analysis of four RCTs
1个月前
已完结
皖公网安备34019202002308
